Lilly, Daiichi launch prasugrel in U.K.
Eli Lilly and Daiichi Sankyo have launched their new heart drug prasugrel (Efient) in the U.K., following its authorization by the European Medicines Agency (EMEA).

Prasugrel is indicated for patients with acute coronary syndrome, who have unstable angina or have had a heart attack. The approval of prasugrel is based upon data from several trials including TRITON-TIMI 38, a global head-to-head superiority trial involving 13,608 patients worldwide, when compared to clopidogrel (Plavix), according to the Indianapolis-based Lilly and the Tokyo-based Daiichi.

Prasugrel is the first new oral antiplatelet to be licensed in the U.K. for more than a decade.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup